JP2005200419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005200419A5 JP2005200419A5 JP2005009439A JP2005009439A JP2005200419A5 JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5 JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- peroxisome proliferator
- composition
- responsive receptor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 29
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 claims description 16
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 201000003076 Angiosarcoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 20
- 239000000556 agonist Substances 0.000 claims 19
- 102000005962 receptors Human genes 0.000 claims 19
- 108020003175 receptors Proteins 0.000 claims 19
- 239000003614 peroxisome proliferator Substances 0.000 claims 17
- 229960005095 pioglitazone Drugs 0.000 claims 10
- 229960001641 troglitazone Drugs 0.000 claims 10
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical group C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 10
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims 6
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims 6
- 229940123934 Reductase inhibitor Drugs 0.000 claims 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 4
- 229960004844 lovastatin Drugs 0.000 claims 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 4
- 229960002855 simvastatin Drugs 0.000 claims 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 4
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002824 peroxisome Anatomy 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53723504P | 2004-01-16 | 2004-01-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005200419A JP2005200419A (ja) | 2005-07-28 |
| JP2005200419A5 true JP2005200419A5 (enExample) | 2008-02-28 |
Family
ID=34619679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005009439A Pending JP2005200419A (ja) | 2004-01-16 | 2005-01-17 | 癌治療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20050209292A1 (enExample) |
| EP (1) | EP1555021A1 (enExample) |
| JP (1) | JP2005200419A (enExample) |
| TW (1) | TWI297606B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590774A (en) * | 2008-08-07 | 2012-09-28 | Pulmagen Therapeutics Inflammation Ltd | Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| US9150534B2 (en) | 2012-02-28 | 2015-10-06 | Northwestern University | Prodrugs of fluorinated mevalonates to inhibit the mevalonate pathway of Streptococcus pneumoniae |
| CA2868311C (en) * | 2012-03-26 | 2021-06-22 | Nippon Chemiphar Co., Ltd. | Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma |
| US9486503B2 (en) | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
| CA3159085A1 (en) * | 2013-01-14 | 2014-07-17 | Clinics Operations Limited | Combination cancer therapeutics and uses thereof |
| JP6527822B2 (ja) | 2013-09-25 | 2019-06-05 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨 |
| EP3612177A4 (en) | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| WO2018195434A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| CA3063717C (en) | 2017-05-19 | 2021-08-24 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| US20240058335A1 (en) * | 2021-01-08 | 2024-02-22 | Duke University | Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| NZ286920A (en) * | 1995-07-03 | 1997-06-24 | Sankyo Co | Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma |
| JP3651816B2 (ja) * | 1995-07-03 | 2005-05-25 | 三共株式会社 | 動脈硬化症予防および治療剤 |
| JP4549443B2 (ja) * | 1996-12-11 | 2010-09-22 | ダナ−ファーバー キャンサー インスティテュート インク． | 腫瘍細胞の成長を阻害するための方法および製薬学的組成物 |
| UA57081C2 (uk) * | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
| CN1329359C (zh) * | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
| US20030060488A1 (en) * | 2000-02-10 | 2003-03-27 | Yasuo Sugiyama | Drug comprising combination |
| WO2002008188A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| JP2002128700A (ja) * | 2000-08-16 | 2002-05-09 | Sankyo Co Ltd | 癌を予防及び治療するための医薬組成物 |
| WO2003053974A1 (en) * | 2001-12-21 | 2003-07-03 | Dr. Reddy's Laboratories Ltd. | Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
-
2005
- 2005-01-17 JP JP2005009439A patent/JP2005200419A/ja active Pending
- 2005-01-17 EP EP05290099A patent/EP1555021A1/en not_active Ceased
- 2005-01-17 TW TW094101363A patent/TWI297606B/zh not_active IP Right Cessation
- 2005-01-18 US US11/037,538 patent/US20050209292A1/en not_active Abandoned
-
2008
- 2008-10-14 US US12/250,923 patent/US20090082406A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005200419A5 (enExample) | ||
| RU2007126483A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| EA200501586A1 (ru) | Фармацевтические продукты | |
| NO20045434L (no) | En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom | |
| IL163931A (en) | Derivatives of Tetrazycline Compounds Converted by Amino Methyl and Pharmaceutical Preparation Containing Them | |
| JP2006526644A5 (enExample) | ||
| NO20033343L (no) | Farmasöytiske doseringsformer av epothiloner for oral administrasjon | |
| EE04990B1 (et) | HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod | |
| MX2007007843A (es) | Formulacion de complejo de inhibidor de 3-hidroxi-3-metil glutaril coa reductasa y agente antihipertensivo, y proceso para su preparacion. | |
| WO2005034908A3 (en) | A solid dosage form comprising a fibrate and a statin | |
| EP2079462A4 (en) | PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELABLE METAL COMPOUNDS AND METALO HDAC HEMMER CHELATE COMPLEXES | |
| MA31432B1 (fr) | Metabolites de derives de (thio) carbamoyl-cyclohexane | |
| BRPI0412557A (pt) | forma de dosagem farmacêutica de eventos cardiovasculares | |
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| DE602004020649D1 (de) | Hdl-verstärkende kombinationstherapie-komplexe | |
| BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EP1619180A4 (en) | CASR ANTAGONIST | |
| NO20074109L (no) | Intravenose formuleringer av PDE-5 inhibitorer | |
| RU2010109452A (ru) | Способы и композиции, предназначенные для лечения раковых заболеваний | |
| EA201401042A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| WO2008013833A3 (en) | Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles | |
| JP2006512361A5 (enExample) | ||
| JP2007512347A5 (enExample) | ||
| BRPI0411623A (pt) | forma de dosagem farmacêutica ou dietética, esporopolenina, método para a formação de uma esporopolenina funcionalizada com amina primária ou um outro revestimento de exina, método para a formação de uma esporopolenina funcionalizada com poliamino ou um outro revestimento de exina de um esporo, método para a obtenção de uma esporopolenina funcionalizada com aminoácido ou um outro revestimento de exina de um esporo, esporopolenina funcionalizada ou um outro revestimento de exina de um esporo, forma de dosagem dietética ou flavorizante, método de preenchimento de revestimentos de exina de esporos, uso da forma de dosagem e método de aplicação oral de um ingrediente ativo | |
| WO2006091575A3 (en) | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |